October 1, 2018
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. The Company's initial approach applies its Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies. In commercializing its technology through strategic collaborations with pharmaceutical and biotech companies, GeneCentric is defining responder populations based on subtypes throughout the drug development cycle.
BACK TO BLOG